Search the Community

Showing results for tags 'keytruda'.

More search options

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


    • LUNG CANCER 101
    • HOPE
    • GRIEF


  • An Advocate's Perspective
  • Cheryncp123's Blog
  • Lung Cancer Stories
  • PeggieH
  • Stay The Course
  • Caregivers Connection
  • Spree
  • Volunteer Voices


There are no results to display.

Found 7 results

  1. My mom was diagnosed with NSCLC and was approved for keytruda. She has a small tumor in her lung and an even smaller, hardly visible one in her liver. Everything else came back clear. The keytruda will be her first treatment. What can we expect from this? Side effects? I know all cancer is different , but I would love to hear from someone who has taken it. Is it even possible this could shrink her liver tumor so they can operate on her lung or lead to remission? She is obviously stage IV so I know it is very serious and I'm worried about how much time I have left with her. My other question is, they never told her the size of the spots in her lung and liver. This may be a dumb question, but do the size of these matter at all or give any indication how advanced it is? She doesn't ask any questions during appointments so I'm trying to learn as much as possible. Thank you in advance for any help you can provide .
  2. Hi. My mom was recently diagnosed with lung cancer, well, they did a biopsy and found cancer in her lung. we don't know yet the stage or origin. she is a long time smoker, but only 53. I am really hoping they found it early, even though I know that is rarely the case. My question today is she has an appointment set and it lists 3 different departments she is meeting with. Radiation/Oncology, Hematology/Oncology, and behavioral medicine. the radiation oncology is obvious , but can anyone tell me what roles the other 2 have in treatment of lung cancer ?
  3. Hello, I have been reading through discussions and posts on here for the last week and it has been a fantastic resource - so much caring and first hand experience and knowledge... it's really a great place. I am here because my father was diagnosed with Stage iv NSCLC with mets to the brain, back on October 25th. He is 67 years old and the diagnosis came quite by accident. He had fallen off of an unstable ladder while changing a light fixture and both his chest and head were impacted from the fall so an X-ray and CT scan were done to rule out breaks. Turned out that they found a lesion on the lung and a spot on his brain. We were all surprised as he had not been experiencing any symptoms. Please bear with me and excuse the lengthy write up - so much has happened in the 9 weeks ... He had a lung biopsy done week of October 24th and in the meantime, we started consultations for Stereotactic Radiation for the small brain tumour (as this needed to be treated right away). Nov. 4th - we met with his general oncologist to review the biopsy results only to be met with the news that they had not been able to gather a good enough sample in order to get the information required to put together a treatment plan. Since we were going to treat the brain first, the biopsy result was not so urgent (as he would not start any chemo until after the brain radiation. Nov. 16th - he underwent the stereotactic radiation treatment. He will go back for a follow up MRI on January 16th to see how the tumour was affected. Dec. 2nd - another meeting with his oncologist to review biopsy results and also review a recent chest scan that had been done earlier in the week. Biopsy confirmed NSCLC Adenocarcinoma (assumed to be wild type, but hey were still awaiting genetic testing results). The review of the scan showed very little change in the size of the tumour. Due to the imaging, the fact that my dad was still not experiencing symptoms and the fact that we were still waiting on some of the biopsy results, the decision was made to not proceed with any treatment, but to wait another two weeks until we had all results in. Dec.16th - Latest testing confirms that there is no presence of EGFR mutation but shows that the tumour does have a PDL-1 expression of greater than 50%, which meant that aside from standard chemotherapy, Ketruda was also an option for treatment. Although, not available under healthcare until a 2nd line setting. Again, seeing as Dad was not experiencing symptoms and it being so close to the holidays, we decided to wait until the new year to decide on the best approach to treatment. (Note: we were considering the private route for first line treatment with Keytruda). We were not due to see the doctor again until January 10th Dec. 20th - My Dad coughed up blood for the first time since being diagnosed. Dec. 22nd - Back to see the doctor to let him know that we felt it necessary to start a treatment right away and based on details from the previous appt., (treatment being more tolerable, outcomes a little more favourable) felt that Keytruda was the right approach and planned to access it via a private infusion clinic. The doctor recommended Cisplatin/ Alimta as a first attempt at treatment based on having the resources of the hospital team available to him and also knowing that Keytruda would be an option for 2nd line. Note: This is the only dr. appointment that I was not able to attend so I did not have the opportunity to ask all of the questions that I wish I could have. To Come- My Dad will have a first round chemotherapy treatment (of Cisplatin and Alimta) on January 6th. Based on my reading, I see that Cisplatin is of the more aggressive/ harsher/ less tolerated treatments. I would be interested in hearing of anyones experience with it. Has anyone here had Keytruda as a first line treatment and what was your experience with that? Also - it's been a long time since the lung cancer diagnosis ... without treatment - Has anyone else had a similar experience where treatment has been delayed due to other circumstances and what was your outcome? I wish you all a happy and healthy 2017. Thank you for your time and input. Stephanie
  4. hello, following two cycles of cisplatin/ alimta we have just returned from the doctor and after reviewing a chest X-ray, he has recommended that we stop the chemotherapy in favour of starting Keyturda treatments next week. my dad is stage IV NSCLC with a PDL-1 greater than 50%. The chest x-ray showed that his lung is collapsed, likely due to the tumour growing in size and obstructing the vessels. I am eager to hear from other people who have been given this treatment and what your experience was. Dad did not tolerate the chemo well, mostly extreme fatigue, not regaining energy until about 18 days. Surgery and Radiation are not options for him, really hoping that this therapy works for him. best wishes, Stephanie
  5. Hi all and thank you in advance for the information and support. My 74 year old mother was diagnosed in June 2016 with stage 4 NSCLC. (Adeno-C, no mutations) upper left lobe tumor with a small lesion in the brain. Because the objective of care was palliative she did not take platinum based chemo and instead went on Alimta (only). She had targeted radiation to the brain (cyberknife) Oct scans were stable, additional scans in December showed progression. Lungs and now liver. She just started keytruda this week. Her pDL =80% She's quite frail and sleeping a ton. I would be interested in hearing from others on Keytruda. I have done all the research and hear promising things but fear her cancer has spread too much/too far. Just looking for any hope or inspiration here. Thank you all so much stephanie
  6. Edward Garon, MD, of UCLA joins the LUNGevity Foundation Scientific Advisory Board Dr. Garon brings expertise in clinical trials and other key areas to LUNGevity’s research program FOR IMMEDIATE RELEASE Media Contact: Austin Courtney (202) 414-0791 WASHINGTON, DC (January 13, 2017) – LUNGevity Foundation, the nation’s preeminent lung cancer research foundation, today announced that Edward Garon, MD, has joined LUNGevity’s Scientific Advisory Board, a group of 19 world-renowned scientists and researchers who guide LUNGevity’s scientific strategy and research program. The Scientific Advisory Board is integral to the Foundation, overseeing the scientific approach and ensuring that grants are awarded to the researchers whose proposals demonstrate the greatest potential for finding lung cancer at its earliest, most treatable phase, as well as extending and improving lives for lung cancer survivors. LUNGevity is the only lung cancer organization with programmatic focuses on early detection and Career Development Awards. LUNGevity-funded researchers are working on finding a better way to detect lung cancer, and to better diagnose, treat, and prevent its recurrence. The research program is a crucial factor in moving the science forward to improve outcomes for people living with lung cancer. Dr. Garon is the Director of the Thoracic Oncology Program at the Jonsson Comprehensive Cancer Center at UCLA and Associate Professor of Medicine in the Division of Hematology-Oncology at David Geffen School of Medicine at UCLA. He has been the principal investigator of peer-reviewed grants from various funding organizations, including the National Cancer Institute. His focus is on clinical research and biomarker development. He has served as the principal investigator on national and international phase I, II, and III clinical trials. Among these are trials that have led to the approval of drugs for the treatment of non-small cell lung cancer, including ramucirumab (Cyramza®) and the immunotherapy pembrolizumab (Keytruda®). “We are honored that Dr. Garon has joined our Scientific Advisory Board,” said Andrea Ferris, President and Chairman of LUNGevity Foundation. “His expertise and advice will be invaluable to furthering LUNGevity’s goal to improve outcomes for lung cancer patients.” Click here to read the complete press release on
  7. On August 17, LUNGevity hosted a webinar with Dr. Julie Brahmer to discuss recent clinical trials in immunotherapy drugs. These trials have stimulated a lot of discussion in the lung cancer community. The webinar was moderated by LUNGevity's Vice President of Support & Surivivorship, Katie Brown. Dr. Julie Brahmer is an immunotherapy expert at Johns Hopkins and a member of LUNGevity Scientific Advisory Board. Dr. Brahmer is an expert in the use of immunotherapies to treat lung cancer. She has spearheaded numerous clinical trials for the immunotherapy of lung cancer, including the pioneering trial that led to the approval of nivolumab in the second-line setting for advanced-stage lung cancer. Dr. Brahmer is the director of the Thoracic Oncology Program at the Johns Hopkins Kimmel Cancer Center. She is also a member of LUNGevity’s Scientific Advisory Board. To listen to the webinar and to read the follow-up blog written by LUNGevity's Director of Science Communications, Dr. Upal Basu Roy, please click here.